IRAK1 inhibitors can attenuate NF-κB signaling in spleen mononuclear cells of lupus-prone lpr mice and SLE patients with PBMCs, while it reduces proinflammatory cytokine production in mice. The gene discussed is NFKB1; the disease is systemic lupus erythematosus.